{"filing":{"accession_number":"0001104659-26-117964","cik":"0001082554","ticker":"UTHR","company_name":"UNITED THERAPEUTICS Corp","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-21","primary_document":"tm2628087d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1082554/000110465926117964/tm2628087d1_8k.htm"},"events":[{"id":37011,"run_id":34113,"accession_number":"0001104659-26-117964","anchor_item_number":"8.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"United Therapeutics' Board approved a $2.0 billion share repurchase program effective through October 21, 2027. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses \"share-repurchase programs\" alongside dividends and distributions. The $2 billion authorization is material to investors as it reflects capital allocation strategy and shareholder value commitment, and the CFO's statement emphasizes confidence in the company's balance sheet and free cash flow position.","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41587,"accession_number":"0001104659-26-117964","item_number":"8.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"United Therapeutics' Board approved a $2.0 billion share repurchase program effective through October 21, 2027. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses \"share-repurchase programs\" alongside dividends and distributions. The $2 billion authorization is material to investors as it reflects capital allocation strategy and shareholder value commitment, and the CFO's statement emphasizes confidence in the company's balance sheet and free cash flow position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:02:13.012629+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41587,"accession_number":"0001104659-26-117964","item_number":"8.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"United Therapeutics' Board approved a $2.0 billion share repurchase program effective through October 21, 2027. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses \"share-repurchase programs\" alongside dividends and distributions. The $2 billion authorization is material to investors as it reflects capital allocation strategy and shareholder value commitment, and the CFO's statement emphasizes confidence in the company's balance sheet and free cash flow position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:02:13.012629+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-10-22"}]}